SCHEMBL10102285

SCHEMBL10102285

COc1ccc2c3c(c4c(c2c1)OC(c1ccccc1)(c1ccc(N2CCCCC2)cc1)C=C4)C1(CCCCCCC1)c1ccccc1-3

nearest known ligand 0.34

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.33
MAOB P27338 1/20 0.30
AVPR1A P37288 1/20 0.30
KDM1A O60341 2/20 0.30
NPY1R P25929 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102398 0.95 MAPT (0.34) MAPT
SCHEMBL26032649 0.93 AKT1 (0.34) MAPT
SCHEMBL10102279 0.92 MAPT (0.32) MAPT
SCHEMBL15763601 0.89 MAPT (0.34) MAPT
SCHEMBL10102281 0.89 MAPT (0.31) MAPT
SCHEMBL10102284 0.89 PDK2 (0.30)
SCHEMBL14617526 0.89 PDK2 (0.30)
SCHEMBL22864324 0.88 ATM (0.34) MAPT
SCHEMBL27393177 0.88 AKT1 (0.34) MAPT
SCHEMBL25954005 0.88 POLB (0.32) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240241291-A1 FUNCTIONAL LAMINATE AND FUNCTIONAL LENS COMPRISING THE FUNCTIONAL LAMINATE TOKUYAMA CORPORATION (JP) 2024-07-18 US disclosed
US-20230272252-A1 ADHESIVE COMPOSITION, LAMINATE AND OPTICAL ARTICLE COMPRISING THE LAMINATE TOKUYAMA CORPORATION (JP) 2023-08-31 US disclosed
US-20230260669-A1 CURABLE COMPOSITION AND CURED BODY OF SAME TOKUYAMA CORPORATION (JP) 2023-08-17 US disclosed
EP-4183579-A1 CURABLE COMPOSITION AND CURED BODY OF SAME Tokuyama Corporation (JP) 2023-05-24 EP disclosed
US-20200386915-A1 FUNCTIONAL LAMINATE AND FUNCTIONAL LENS COMPRISING THE FUNCTIONAL LAMINATE TOKUYAMA CORPORATION (JP) 2020-12-10 US disclosed
EP-3495441-B1 ADHESIVE COMPOSITION, LAMINATE, AND OPTICAL ARTICLE INCLUDING SAID LAMINATE TOKUYAMA CORP (JP) 2020-10-21 EP disclosed
US-20200283662-A1 ADHESIVE COMPOSITION, LAMINATE AND OPTICAL ARTICLE COMPRISING THE LAMINATE TOKUYAMA CORPORATION (JP) 2020-09-10 US disclosed
US-10690943-B2 Laminate and optical article comprising the same TOKUYAMA CORPORATION (JP) 2020-06-23 US disclosed
EP-2602300-B1 PHOTOCHROMIC COMPOSITION TOKUYAMA CORP (JP) 2019-06-12 EP disclosed
US-20190004336-A1 LAMINATE AND OPTICAL ARTICLE COMPRISING THE SAME TOKUYAMA CORPORATION (JP) 2019-01-03 US disclosed
EP-2602300-A1 PHOTOCHROMIC COMPOSITION Tokuyama Corporation (JP) 2013-06-12 EP disclosed
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
EP-2275418-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2012-10-17 EP disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
EP-2377902-A1 COATING COMPOSITION, PROCESS FOR PRODUCTION OF THE COMPOSITION, AND LAMINATE WITH HARD COAT LAYER Tokuyama Corporation (JP) 2011-10-19 EP disclosed
US-20110244244-A1 COATING COMPOSITION, PROCESS FOR PRODUCING THE COMPOSITION, AND LAMINATE HAVING A HARD COAT LAYER TOKUYAMA CORPORATION (JP) 2011-10-06 US disclosed
US-20110244244-A1 COATING COMPOSITION, PROCESS FOR PRODUCING THE COMPOSITION, AND LAMINATE HAVING A HARD COAT LAYER TOKUYAMA CORPORATION (JP) 2011-10-06 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
EP-2275418-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 MAPT 3134/4885MAOB 1895/4885AVPR1A 1443/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 MAPT 4740/4885MAOB 1845/4885AVPR1A 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.